

U.S.S.N.: 08/823,999  
Filed: March 25, 1997  
AMENDMENT

composition comprising a compound which specifically inhibits or reduces leukocyte CD11/CD18 integrin-mediated adhesion or function, wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with CD11/CD18 integrins or their ligands and which block the interaction of the CD11/CD18 integrins or their ligands with vascular cells; molecules which inhibit expression of the CD11/CD18 integrins or their ligands, and peptides and peptidomimetics derived from the CD11/CD18 integrins or their ligands which block the interaction of the CD11/CD18 integrins or their ligands with vascular cells or tissues, in an amount effective to inhibit or reduce stenosis or dependent restenosis of a blood vessel following injury to vascular tissue.

5. (amended) The method of claim 1 wherein the integrin is selected from the group consisting of Mac-1 (CD11b/CD18), LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18.

6. (amended) The method of claim 5 wherein the CD11/CD18 integrin is Mac-1.

8. (amended) The method of claim 1 wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with CD11/CD18 integrins or their ligands and which block the interaction of the CD11/CD18 integrins or their ligands with vascular cells; molecules which inhibit expression of the integrins or their ligands, and peptides and peptidomimetics derived from the integrins or their ligands which block the interaction of the integrins or their ligands with vascular cells or tissues].

9. (amended) The method of claim 5 wherein the CD11/CD18 integrin is LFA-1 and the ligand is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3.